Truist Securities Maintains Buy on Disc Medicine, Raises Price Target to $115
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $83 to $115.
Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $83 to $115.